Arvin Capital Management’s Bio-Techne TECH Stock Holding History

Arvin Capital Management’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-84,800	Closed	-$4.99M	–	70
2025 Q4	$4.99M	Sell	84,800 -143,200	-63%	-$8.7M	0.94%	30
2025 Q3	$12.7M	Buy	+228,000	New	+$12.2M	2.29%	17

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arvin Capital Management's TECH Position: Q2 2026 in Review

Arvin Capital Management sold out of Bio-Techne (TECH) in Q2 2026, closing a stake of 204,304 shares — an estimated $10.7M sold.

Arvin Capital Management first reported a position in TECH in Q2 2025 and held it in 3 quarters. The position peaked at $17.6M in Q4 2025. 595 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

Arvin Capital Management reported no remaining Bio-Techne position as of Q2 2026 after selling out during the quarter.
Arvin Capital Management sold 204,304 Bio-Techne shares in Q2 2026, an estimated $10.7M.
Arvin Capital Management first reported a position in Bio-Techne in Q2 2025 and held it in 3 quarters.
Arvin Capital Management's Bio-Techne position peaked at $17.6M in Q4 2025.
595 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Arvin Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.